嵌合抗原受体T细胞（CAR-T）疗法后基于下一代测序的微小残留病的预测价值 - Suppr | 超能文献

相似文献

1

Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法后基于下一代测序的微小残留病的预测价值

Bone Marrow Transplant. 2022 Aug;57(8):1350-1353. doi: 10.1038/s41409-022-01699-2. Epub 2022 Jun 1.

2

[Cell therapy's poster child: Chimeric antigen receptor T cell therapy].[细胞疗法的典型代表：嵌合抗原受体T细胞疗法]

Sheng Wu Gong Cheng Xue Bao. 2019 Dec 25;35(12):2339-2349. doi: 10.13345/j.cjb.190291.

3

Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.嵌合抗原受体（CAR）T 细胞治疗 B 细胞恶性肿瘤患者的疗效和安全性的系统评价和荟萃分析方案。

Syst Rev. 2021 Jan 21;10(1):35. doi: 10.1186/s13643-021-01588-7.

4

Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.针对表达在乳腺癌细胞上的叶酸受体 α 抗原的第四代嵌合抗原受体 T 细胞用于过继性 T 细胞疗法。

Breast Cancer Res Treat. 2021 Feb;186(1):25-36. doi: 10.1007/s10549-020-06032-3. Epub 2021 Jan 3.

5

What a headache! Double-hit lymphoma with CNS recurrence - Role of chimeric antigen receptor (CAR) T-cell therapy.真是令人头疼！伴有中枢神经系统复发的双打击淋巴瘤——嵌合抗原受体（CAR）T细胞疗法的作用

Leuk Lymphoma. 2020 Apr;61(4):757-762. doi: 10.1080/10428194.2019.1695052. Epub 2019 Nov 25.

6

Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法的眼科影响

Semin Ophthalmol. 2021 May 19;36(4):329-334. doi: 10.1080/08820538.2021.1897857. Epub 2021 Mar 10.

7

[Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].[实体瘤嵌合抗原受体T（CAR-T）细胞疗法的进展：综述]

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019 Oct;35(10):944-948.

8

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.嵌合抗原受体 T 细胞（CAR-T）治疗使伴有微小残留病的 B 细胞急性淋巴细胞白血病患者获得持久缓解。

Cancer Immunol Immunother. 2021 Dec;70(12):3501-3511. doi: 10.1007/s00262-021-02941-4. Epub 2021 Apr 25.

9

Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.克服嵌合抗原受体 T 细胞疗法副作用的策略。

Ann N Y Acad Sci. 2022 Apr;1510(1):18-35. doi: 10.1111/nyas.14724. Epub 2022 Jan 4.

10

[Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].[嵌合抗原受体T细胞（CAR-T）疗法治疗难治性/复发性血液系统恶性肿瘤]

Rinsho Ketsueki. 2018;59(10):1948-1954. doi: 10.11406/rinketsu.59.1948.

引用本文的文献

1

Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment.微小残留病检测：对临床诊断和癌症患者治疗的意义

MedComm (2020). 2025 May 15;6(6):e70193. doi: 10.1002/mco2.70193. eCollection 2025 Jun.

2

Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions.癌症诊断与治疗中的下一代测序：临床应用与未来方向。

Discov Oncol. 2025 Apr 20;16(1):578. doi: 10.1007/s12672-025-01816-9.

3

NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk.